Androgen Receptor Point Mutations: A Mechanism of Therapeutic Resistance and a Framework for Rational Drug Design

Area of Science:

• Oncology
• Molecular Biology
• Structural Biology

Background:

• Therapeutic resistance in castration-resistant prostate cancer (CRPC) is increasingly linked to point mutations in the androgen receptor (AR) ligand-binding domain (LBD).
• These mutations alter AR structure and function, leading to treatment failure of AR pathway inhibitors (ARPIs).

Purpose of the Study:

• To review how AR LBD point mutations induce molecular changes that cause ARPI treatment failure in CRPC.
• To explore structural insights into AR mutations and their impact on ARPI efficacy.

Main Methods:

• Searched PubMed for structural studies on the AR LBD, focusing on molecular docking and ligand-receptor interactions.
• Utilized Protein Data Bank (PDB) for structural data of wild-type and mutant AR LBDs obtained via X-ray diffraction.
• Analyzed crystallography and in silico data to understand structural changes and their functional consequences.

Main Results:

• AR LBD mutations can cause a functional shift, converting AR inhibitors into activators.
• Changes in steric hindrance within the AF-2 domain of the AR LBD are implicated in ARPI loss of function.
• New therapeutic strategies involve combination approaches and targeting other AR domains, but clinical progression is limited.

Conclusions:

• Understanding AR LBD structural changes is crucial for rationally designing next-generation AR-targeting therapeutics.
• Computational modeling should be employed to streamline drug discovery and development for overcoming therapeutic resistance.
• Further research is needed to identify optimal strategies for new AR-targeted therapies in CRPC.